Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Dennis Morrison"'
Autor:
Dennis Morrison, Sandip Roy, Craig Rayner, Ahmed Amer, Dan Howard, James R Smith, Thomas G Evans
Publikováno v:
PLoS ONE, Vol 2, Iss 12, p e1305 (2007)
The threat of potential pandemic influenza requires a reevaluation of licensed therapies for the prophylaxis or treatment of avian H5N1 infection that may adapt to man. Among the therapies considered for use in pandemic influenza is the co-administra
Externí odkaz:
https://doaj.org/article/1a7ec5bf3c1c4495a569fc8c17f82949
Publikováno v:
Clinical Interventions in Aging
Kevin J Ruff,1 Dennis Morrison,2 Sarah A Duncan,2 Matthew Back,1 Cem Aydogan,3 Jason Theodosakis4 1ESM Technologies, LLC, Carthage, MO, USA; 2QPS Bio-Kinetic, Springfield, MO, USA; 3Phytonet AG, Schindellegi, Switzerland; 4University of Arizona Colle
Autor:
Lester I. Harrison, Christian Zurth, Dale Bourg, Adel H. Karara, Linda Bourg, Nagaraju Poola, Dennis Morrison, Armen P. Melikian
Publikováno v:
The Journal of Clinical Pharmacology. 54:520-527
Two open-label, randomized, two-period, crossover studies were performed to determine the safety, delivery rates, and pharmacokinetic properties of a combination estradiol (E2)/levonorgestrel (LNG) transdermal delivery system (TDS). Study 1 enrolled
Autor:
Peter H. Tsang, David Fried, Victoria Landolfi, Ann R. Falsey, Ayca Ozol-Godfrey, Dennis Morrison, John E. Ervin, Geoffrey J. Gorse, David P. Greenberg, Carol M. Johnson
Publikováno v:
Vaccine. 31:6034-6040
Background This clinical trial examined the safety and immunogenicity of annual revaccination with Fluzone ® Intradermal (Sanofi Pasteur, Swiftwater, PA) vaccine compared to a standard intramuscular (IM) split-virion trivalent influenza vaccine (Flu
Autor:
Tommy Andersson, Dennis Morrison, Péter Nagy, Jaya Pisupati, Jared Schettler, Timothy D. Warner
Publikováno v:
American Journal Cardiovascular Drugs. 12:217-224
Autor:
Xiaodong Li, Matthew D. Troyer, Wen Liu, John A. Wagner, Eric Mangin, Dennis Morrison, Sean Gill, Hong Sun, Deborah Panebianco, Jacqueline B. McCrea, Ka Lai Yee
Publikováno v:
Journal of psychopharmacology (Oxford, England). 29(11)
A double-blind crossover study investigated psychomotor effects, pharmacokinetics, and safety of the orexin receptor antagonist suvorexant with and without alcohol. Healthy adults ( n=31) were randomized to receive placebo or suvorexant (40 mg) plus
Autor:
Scott Kitchener, Jean Lang, Xiaochu Duan, Marie-Jose Quentin-Millet, Philip Bedford, Richard A. Nichols, Thomas H. Ermak, Remi Forrat, Farshad Guirakhoo, Karen McCarthy, Dennis Morrison, Thomas P. Monath, Niranjan Kanesa-thasan, Sutee Yoksan
Publikováno v:
Human Vaccines. 2:60-67
A randomized double-blind Phase I Trial was conducted to evaluate safety, tolerability, and immunogenicity of a yellow fever (YF)-dengue 2 (DEN2) chimera (ChimeriVax-DEN2) in comparison to that of YF vaccine (YF-VAX). Forty-two healthy YF naive adult
Autor:
Adel H, Karara, Lester I, Harrison, Armen P, Melikian, Nagaraju, Poola, Dennis, Morrison, Dale, Bourg, Linda, Bourg, Christian, Zurth
Publikováno v:
Journal of clinical pharmacology. 54(5)
Two open-label, randomized, two-period, crossover studies were performed to determine the safety, delivery rates, and pharmacokinetic properties of a combination estradiol (E2)/levonorgestrel (LNG) transdermal delivery system (TDS). Study 1 enrolled
Autor:
Timothy D. Warner, Tommy B. Andersson, Dennis Morrison, Jaya Pisupati, Peter Nagy, Jared Schettler
Publikováno v:
ResearcherID
Background The absence of a pharmacokinetic interaction between the proton pump inhibitor esomeprazole (40 mg) and acetylsalicylic acid (aspirin, ASA; 325 mg) has previously been established. Objective This study set out to investigate the potential
Publikováno v:
The European journal of contraceptionreproductive health care : the official journal of the European Society of Contraception. 14(3)
To evaluate the pharmacokinetics of a combined oral contraceptive (OC) containing oestradiol valerate/dienogest (E2V/DNG) administered according to a four-phasic dosing regimen with an oestrogen step-down and a progestin step-up over 26 days of activ